Pharma Stocks
-
Focus on injectable drug packaging growth
SCHOTT Pharma has reported solid first-quarter results driven by demand for injectable drug packaging, with the stock trading near its…
Read More » -
Pharma and tech group eyes growth in US markets
Merck KGaA reports solid Q1 2026 results with growth in its life science and healthcare segments, drawing attention from US…
Read More » -
Is It Too Late To Consider Indivior Pharmaceuticals (INDV) After Its 261% One-Year Surge?
Investors may be wondering if Indivior Pharmaceuticals at US$39.60 is still offering value after its strong run, or if most…
Read More » -
Lexicon Pharmaceuticals (LXRX) Quarterly Revenue Drop Reinforces Concerns Over Persistent Losses
Lexicon Pharmaceuticals (LXRX) just closed FY 2025 with fourth quarter revenue of US$5.5 million and a basic EPS loss of…
Read More » -
Traws Pharma Stock Jumps As Biotech Targets Hantavirus After Cruise Ship Deaths
NEWTOWN, Pa., May 8, 2026, 13:12 (ET) Traws Pharma Inc. on Friday announced plans to push ahead with possible clinical…
Read More » -
Jazz Pharmaceuticals plc Just Beat Earnings Expectations: Here’s What Analysts Think Will Happen Next
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) investors will be delighted, with the company turning in some strong numbers with its latest results.…
Read More » -
Are Estimate Revisions Reshaping ANI Pharmaceuticals’ (ANIP) Earnings Narrative After Its Q1 2026 Call?
ANI Pharmaceuticals, Inc. reported its Q1 2026 results and hosted its earnings call on May 8, 2026, after pre-announcing the…
Read More » -
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Beats Revenue Estimates
Crinetics Pharmaceuticals, Inc. (CRNX) came out with a quarterly loss of $1.23 per share versus the Zacks Consensus Estimate of…
Read More » -
Jazz Pharmaceuticals Stock Surged 105% Over the Past Year. Here’s What’s Driving the Move
Key Takeaways: Jazz Pharmaceuticals (JAZZ) is a biopharmaceutical company focused on developing and commercializing products for unmet medical needs, with…
Read More » -
Is TAK-881’s Reduced-Volume PID Infusion Data Altering The Investment Case For Takeda (TSE:4502)?
Earlier this month, Takeda Pharmaceutical reported that its pivotal Phase 2/3 trial of investigational PID therapy TAK-881 met its primary…
Read More »